Alpha-1-antitrypsin-deficiency is associated with lower cardiovascular risk: an approach based on federated learning

Table 1 Baseline characteristics of the combined study population. For ’Number of individuals’ the percentage values correspond to the total number of COPD patients, for gender and nicotine abuse to the specific sub-cohort (i.e., COPD total, non-AATD, AATD, respectively). p-values are calculated using the Chi-squared test for categorical variables or t-test for comparing the mean values

Variable	COPD total	AATD	Non-AATD	p-value
Number of individuals	43,057	746 (1.73%)	42,311 (98.27%)
Gender (Male)	26,554 (61.67%)	475 (63.67%)	26,079 (61.64%)	0.273
Nicotine Abuse¹	6897 (16.02%)	170 (22.79%)	6727 (15.9%)	< 0.001
^∗Age at first admission	70.13 (12.28)	65.87 (10.84)	70.17 (12.27)	< 0.001
^∗Age at last discharge	70.47 (12.9)	66.51 (12.56)	70.5 (12.9)	< 0.001
^∗Number of visits	2.19 (2.52)	3.08 (3.38)	2.18 (2.5)	< 0.001
Asthma²	830 (3.22%)	11 (1.82%)	819 (3.25%)	0.06412
^∗Neutrophils³	8.53	8.95 (6.7)	8.52 (6.78)	0.4829
^∗Haemoglobin⁴	50.87	23.8 (9.86)	51.31 (13.83)	< 0.001
^∗Platelets	264.88	246.1 (128.3)	265.17 (120.76)	0.0001
^∗Lymphocytes³	3.15	4.11 (7.67)	3.14 (7.07)	0.0688
^∗Procalcitonin⁵	2.07	2.09 (7.85)	2.07 (11.1)	0.9738
^∗CRP	42.94	60.19 (73.99)	42.65 (62.98)	< 0.001

^* Presented as mean (SD), AATD: Alpha 1-Antitrypsin Deficiency, ¹Results are just for five sites due to disclosure risks in the Site C cohort, ² Results are for all sites except for Site B und Site D, ³ differences between groups calculated for all sites except for Site E and Site F, ⁴ differences between groups calculated for all sites except for Site A, ⁵ differences between groups calculated for all sites except for Site E

ISSN: 1465-993X